Medical device firm Focal Therapeutics is highlighting research presented at the 2014 American Brachytherapy Society annual meeting in San Diego that supports the effectiveness of its BioZorb 3D surgical marker.
Dr. Robert Kuske, of Arizona Breast Cancer Specialists, and colleagues reported their experience using BioZorb in 20 patients who underwent breast conservation surgery. The women subsequently received whole-breast irradiation plus boost interstitial irradiation, the company said.
There were no complications in the group. Kuske's team noted significant improvement in their ability to delineate the target volume using the 3D marker, according to Focal Therapeutics.
BioZorb has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The device is available in a range of sizes to accommodate a variety of clinical situations. Its open-spiral design incorporates six permanent titanium clips in a fixed 3D array, and provides specific landmarks at the site of the excised tumor. It is made of a bioabsorbable material that allows the patient's body to absorb the material slowly, so it does not require surgical removal after treatment is complete, the company said.
